<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1134-8046</journal-id>
<journal-title><![CDATA[Revista de la Sociedad Española del Dolor]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Soc. Esp. Dolor]]></abbrev-journal-title>
<issn>1134-8046</issn>
<publisher>
<publisher-name><![CDATA[Inspira Network Group, S.L ]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1134-80462018000100037</article-id>
<article-id pub-id-type="doi">10.20986/resed.2017.3575/2017</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Usos potenciales de la mirtazapina en cuidados paliativos más allá de su efecto antidepresivo]]></article-title>
<article-title xml:lang="en"><![CDATA[Potential use of mirtazapine in palliative care patients beyond from its antidepressant action]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García-Muñoz]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Licona-Galicia]]></surname>
<given-names><![CDATA[D.G.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Juárez de México, SSA Servicio de Clínica de Dolor y Cuidados Paliativos ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>02</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>02</month>
<year>2018</year>
</pub-date>
<volume>25</volume>
<numero>1</numero>
<fpage>37</fpage>
<lpage>44</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1134-80462018000100037&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1134-80462018000100037&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1134-80462018000100037&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN La evaluación y el tratamiento de los trastornos psiquiátricos son cruciales en los padecimientos al final de la vida. La depresión y los trastornos de ansiedad son altamente prevalentes y no deben ser tomados como parte de la normalidad en los pacientes en cuidados paliativos, ya que están asociados a disminución de la calidad de vida, así como mayor morbilidad y mortalidad. Las herramientas de tratamiento farmacológico de estos padecimientos incluyen a los antidepresivos tricíclicos o a los inhibidores selectivos de la recaptura de serotonina que pudiesen no ser los más adecuados por sus efectos adversos e interacciones medicamentosas. Uno de los fármacos que se ocupa relativamente poco en estos contextos es la mirtazapina. La mirtazapina es un fármaco aprobado para el tratamiento de la depresión que se ha probado tiene un inicio de acción más rápido y mayor efectividad que diversos otros antidepresivos. Su mecanismo de acción es distintivo, pues tiene al antagonismo del receptor alfa-2 adrenérgico y el antagonismo del receptor 5-HT2a y c como sus principales actividades sin involucrar a la inhibición del transportador de serotonina. Además cuenta con el bloqueo del receptor 1 de histamina y del receptor 5-HT3 dentro de sus afinidades que le proporcionan actividad como hipnótico-sedante, antiemético y orexigénico. Por su mecanismo noradrenérgico y serotoninérgico también tiene efectos sobre el dolor crónico. Estos factores pueden ser potencialmente útiles en los pacientes tratados en unidades de cuidados paliativos y generarían una reducción de la polifarmacia o del uso de fármacos que pudiesen generar efectos adversos indeseables en esta población. Esta revisión tiene la finalidad de presentar la evidencia del uso de este fármaco en diversos contextos relacionados con la atención de los pacientes en cuidados paliativos, principalmente aquellos que se encuentran al final de la vida, así como establecer su perfil de seguridad en comparación con los antidepresivos clásicamente utilizados.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT Evaluation and treatment of psychiatric disorders is crucial in palliative care patients at the end of life. Depression and anxiety disorders are highly prevalent and should not have been taken as normal in palliative care patients, as they are associated with decreased quality of life and increased morbidity and mortality. The pharmacological treatment of these disorders include selective serotonin reuptake inhibitors and tricyclic antidepressants that should not be the most suitable options because adverse effects and drug interactions associated with them. One of the drugs that is not used often in these contexts is mirtazapine. Mirtazapine is an approved drug for the treatment of depression that has proven to have a faster onset of action and greater effectiveness than several other antidepressants. Its mechanism of action is distinctive because alpha2 adrenergic receptor antagonism and 5-HT2a-c receptor antagonism are the main antidepressant mechanism without involving inhibition of the serotonin transporter. It also has activity as an antagonist of the histamine 1 and the 5-HT3 receptors which produce its hypnotic-sedative, antiemetic and orexigenic properties. By its noradrenergic and serotonergic mechanism also has effects on chronic pain. This factors may be potentially useful in patients treated in palliative care units and also, could reduce polypharmacy or the use of drugs that are likely to generate undesirable adverse effects. The purpose of this review is to show evidence of the use of this drug in various contexts related to palliative care patients, mainly those at the end of life, as well as to establish their safety profile in comparison with tipically used antidepressants.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Mirtazapine]]></kwd>
<kwd lng="en"><![CDATA[pain]]></kwd>
<kwd lng="en"><![CDATA[antideppresant]]></kwd>
<kwd lng="en"><![CDATA[palliative]]></kwd>
<kwd lng="es"><![CDATA[Mirtazapina]]></kwd>
<kwd lng="es"><![CDATA[dolor]]></kwd>
<kwd lng="es"><![CDATA[antidepresivo]]></kwd>
<kwd lng="es"><![CDATA[paliativos]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schatzberg]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Nemeroff]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[The American Psychiatric Publishing Textbook of Psychopharmacology]]></source>
<year>2009</year>
<edition>4th edition</edition>
<publisher-loc><![CDATA[Philadelphia ]]></publisher-loc>
<publisher-name><![CDATA[American Psychiatric Publishing]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Anxiety, depression and quality of life of cancer patients undergoing radiation therapy a cross-sectional study in a community hospital outpatient centre]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Frick]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Tyroller]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Panzer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur J Cancer Care]]></source>
<year>2007</year>
<volume>16</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>130-6</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Associations of depressive symptoms and pain with dialysis adherence, health resource utilization, and mortality in patients receiving chronic hemodialysis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Weisbord]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Mor]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Sevick]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Shields]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Rollman]]></surname>
<given-names><![CDATA[BL]]></given-names>
</name>
<name>
<surname><![CDATA[Palevsky]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Arnold]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin J Am Soc Nephrol]]></source>
<year>2014</year>
<volume>9</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1594-602</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Risk factors for suicidal ideation in patients feeling severely affected by multiple sclerosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Strupp]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ehmann]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Galushko]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bücken]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Perrar]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Hamacher]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[J Palliat Med]]></source>
<year>2016</year>
<volume>19</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>523-8</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Burdensome physical and depressive symptoms predict heart failure-specific health status over one year]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lum]]></surname>
<given-names><![CDATA[HD]]></given-names>
</name>
<name>
<surname><![CDATA[Carey]]></surname>
<given-names><![CDATA[EP]]></given-names>
</name>
<name>
<surname><![CDATA[Fairclough]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Plomondon]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Hutt]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Rumsfeld]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<source><![CDATA[J Pain Symptom Manage]]></source>
<year>2016</year>
<volume>51</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>963-70</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Depression, antidepressants, and bone health in older adults a systematic review]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gebara]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Shea]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Lipsey]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
<name>
<surname><![CDATA[Teitelbaum]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Civitelli]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Müller]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
</person-group>
<source><![CDATA[J Am Geriatr Soc]]></source>
<year>2014</year>
<volume>62</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1434-41</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Investigating polypharmacy and drug burden index in hospitalised older people]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Best]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Gnjidic]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Hilmer]]></surname>
<given-names><![CDATA[SN]]></given-names>
</name>
<name>
<surname><![CDATA[Naganathan]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[McLachlan]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Intern Med J]]></source>
<year>2013</year>
<volume>43</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>912-8</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Onder]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Liperoti]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Foebel]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fialova]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Topinkova]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Polypharmacy and mortality among nursing home residents with advanced cognitive impairment results from the shelter study]]></article-title>
<collab>van der Roest HG</collab>
<source><![CDATA[J Am Med Dir Assoc]]></source>
<year>2013</year>
<volume>14</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>450</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Polypharmacy and medication regimen complexity as risk factors for hospitalization among residents of long-term care facilities a prospective cohort study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lalic]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sluggett]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
<name>
<surname><![CDATA[Ilomäki]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wimmer]]></surname>
<given-names><![CDATA[BC]]></given-names>
</name>
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
<name>
<surname><![CDATA[Robson]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[J Am Med Dir Assoc]]></source>
<year>2016</year>
<volume>17</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1067</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="book">
<collab>American Psychiatry Association</collab>
<source><![CDATA[Diagnostic and statistical manual of mental disorders]]></source>
<year>2013</year>
<edition>5th edition</edition>
<publisher-loc><![CDATA[Philadelphia ]]></publisher-loc>
<publisher-name><![CDATA[American Psychiatric Publishing]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="book">
<collab>PDQ Supportive and Palliative Care Editorial Board</collab>
<source><![CDATA[Depression (PDQ(r)): Health Professional Version. Bethesda,]]></source>
<year>2016</year>
<publisher-loc><![CDATA[MD ]]></publisher-loc>
<publisher-name><![CDATA[National Cancer Institute]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Depression on dialysis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chilcot]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wellsted]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Da Silva-Gane]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Farrington]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[Nephron Clin Pract]]></source>
<year>2008</year>
<volume>108</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>c256-64</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Depression in older adults a palliative medicine perspective]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jordan]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Malhotra]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Maree]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Schenker]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Arnold]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Reynolds]]></surname>
<given-names><![CDATA[CF]]></given-names>
</name>
</person-group>
<source><![CDATA[Harv Rev Psychiatry]]></source>
<year>2015</year>
<volume>23</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>343-53</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Depression as a predictor of disease progression and mortality in cancer patients a metaanalysis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Satin]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Linden]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Phillips]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer]]></source>
<year>2009</year>
<volume>115</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>5349-61</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Depression and oropharynx cancer outcome]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shinn]]></surname>
<given-names><![CDATA[EH]]></given-names>
</name>
<name>
<surname><![CDATA[Valentine]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Jethanandani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Basen-Engquist]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Fellman]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Urbauer]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Psychosom Med]]></source>
<year>2016</year>
<volume>78</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>38-48</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fawcett]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Barkin]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
</person-group>
<source><![CDATA[J Clin Psychiatr]]></source>
<year>1998</year>
<volume>59</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>128-30</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Comparative efficacy and acceptability of 12 new-generation antidepressants a multiple-treatments meta-analysis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cipriani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Furukawa]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Salanti]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Geddes]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Higgins]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Churchill]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Lancet]]></source>
<year>2009</year>
<volume>373</volume>
<numero>9665</numero>
<issue>9665</issue>
<page-range>746-58</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients A STAR*D Report]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fava]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rush]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Wisniewski]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Nierenberg]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Alpert]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[McGrath]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Psychiatry]]></source>
<year>2006</year>
<volume>163</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1161-12</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guelfi]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Ansseau]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Timmerman]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Kørsgaard]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[J Clin Psychopharmacol]]></source>
<year>2001</year>
<volume>21</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>425-31</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Psychiatric disorders in Mexico lifetime prevalence in a nationally representative sample]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Medina-Mora]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Borges]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Benjet]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lara]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Berglund]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Br J Psychiatry]]></source>
<year>2007</year>
<volume>190</volume>
<page-range>521-8</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Anxiety disorders in cancer patients their nature, associations, and relation to quality of life]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stark]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Kiely]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Velikova]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[House]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Selby]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[J Clin Oncol]]></source>
<year>2002</year>
<volume>20</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>3137-48</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Anxiety disorders in adults treated by hemodialysis a single-center study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cukor]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Coplan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Friedman]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Newville]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Safier]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[AM J Kidney Dis]]></source>
<year>2008</year>
<volume>52</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>128-36</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Mirtazapine treatment of generalized anxiety disorder a fixed dose, open label study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gambi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[De Berardis]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Campanella]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Carano]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sepede]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Salini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[J Psychopharmacol]]></source>
<year>2005</year>
<volume>19</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>483-7</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A trilogy case review highlighting the clinical and pharmacologic applications of mirtazapine in reducing polypharmacy for anxiety, agitation, insomnia, depression, and sexual dysfunction]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barkin]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Chor]]></surname>
<given-names><![CDATA[PN]]></given-names>
</name>
<name>
<surname><![CDATA[Braun]]></surname>
<given-names><![CDATA[BG]]></given-names>
</name>
<name>
<surname><![CDATA[Schwer]]></surname>
<given-names><![CDATA[WA]]></given-names>
</name>
</person-group>
<source><![CDATA[J Clin Psychiatry]]></source>
<year>1999</year>
<volume>1</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>142-5</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Mirtazapine in generalized social anxiety disorder a randomized, double-blind, placebo-controlled study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schutters]]></surname>
<given-names><![CDATA[SI]]></given-names>
</name>
<name>
<surname><![CDATA[Van Megen]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Van Veen]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Denys]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Westenberg]]></surname>
<given-names><![CDATA[HG]]></given-names>
</name>
</person-group>
<source><![CDATA[Int Clin Psychopharmacol]]></source>
<year>2010</year>
<volume>25</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>302-4</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms an 8-week open-label randomised paroxetine-controlled trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Yoon]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jung]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
<name>
<surname><![CDATA[Jeong]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
<name>
<surname><![CDATA[Cho]]></surname>
<given-names><![CDATA[HB]]></given-names>
</name>
</person-group>
<source><![CDATA[Int J Clin Pract]]></source>
<year>2011</year>
<volume>65</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>323-9</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Mirtazapine in the treatment of mood and anxiety disorders]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ostacher]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Eisner]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Nierenberg]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
</person-group>
<source><![CDATA[Expert Rev Neurother]]></source>
<year>2003</year>
<volume>3</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>425-33</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fawcett]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Barkin]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
</person-group>
<source><![CDATA[J Clin Psychiatry]]></source>
<year>1998</year>
<volume>59</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>123-7</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Care of depressed patients with anxiety symptoms]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nutt]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
</person-group>
<source><![CDATA[J Clin Psychiatry]]></source>
<year>1999</year>
<volume>60</volume>
<numero>Suppl 17</numero>
<issue>Suppl 17</issue>
<page-range>23-7</page-range></nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Katzman]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Bleau]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Bier]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Chokka]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Kjernisted]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Van Ameringen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[BMC Psychiatry]]></source>
<year>2014</year>
<volume>14</volume>
<numero>Suppl 1</numero>
<issue>Suppl 1</issue>
<page-range>S1</page-range></nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heinze Martin]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Camacho Segura]]></surname>
<given-names><![CDATA[PV]]></given-names>
</name>
</person-group>
<source><![CDATA[Guía clínica para el manejo de la ansiedad]]></source>
<year>2010</year>
<publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[Instituto Nacional de Psiquiatría]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Mirtazapine improves sleep and lowers anxiety and depression in cancer patients superiority over imipramine]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cankurtaran]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[Ozalp]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Soygur]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Akbiyik]]></surname>
<given-names><![CDATA[DI]]></given-names>
</name>
<name>
<surname><![CDATA[Turhan]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Alkis]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<source><![CDATA[Support Care Cancer]]></source>
<year>2008</year>
<volume>16</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1291-8</page-range></nlm-citation>
</ref>
<ref id="B33">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trimble]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[George]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<source><![CDATA[Biological Psychiatry]]></source>
<year>2010</year>
<page-range>1-30</page-range><publisher-loc><![CDATA[Oxford, UK ]]></publisher-loc>
<publisher-name><![CDATA[Wiley-Blackwell]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B34">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stahl]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Muntner]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<source><![CDATA[Stahl's essential Psychopharmacology. Neuroscientific Basis and practical Applications]]></source>
<year>2013</year>
<edition>Fourth Edition</edition>
<publisher-loc><![CDATA[Cambrige, UK ]]></publisher-loc>
<publisher-name><![CDATA[Cambridge University Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B35">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Research report benzodiazepine initiation and dose escalation a risk factor for inpatient falls]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Skinner]]></surname>
<given-names><![CDATA[BW]]></given-names>
</name>
<name>
<surname><![CDATA[Johnston]]></surname>
<given-names><![CDATA[EV]]></given-names>
</name>
<name>
<surname><![CDATA[Saum]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
</person-group>
<source><![CDATA[Ann Pharmacoter]]></source>
<year>2017</year>
<volume>51</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>281-5</page-range></nlm-citation>
</ref>
<ref id="B36">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Use of benzodiazepines and association with falls in older people admitted to hospital a prospective cohort study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ballokova]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Peel]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
<name>
<surname><![CDATA[Fialova]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Scott]]></surname>
<given-names><![CDATA[IA]]></given-names>
</name>
<name>
<surname><![CDATA[Gray]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Hubbard]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
</person-group>
<source><![CDATA[Drugs Aging]]></source>
<year>2014</year>
<volume>31</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>299-310</page-range></nlm-citation>
</ref>
<ref id="B37">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Association between benzodiazepine use and dementia A meta-analysis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhong]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<source><![CDATA[PLoS One]]></source>
<year>2015</year>
<volume>10</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1-16</page-range></nlm-citation>
</ref>
<ref id="B38">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Benzodiazepines and the risk of urinary incontinence in frail older persons living in the community]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Landi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Cesari]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Russo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Onder]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Sgadari]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bernabei]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Pharmacol Ther]]></source>
<year>2002</year>
<volume>72</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>729-34</page-range></nlm-citation>
</ref>
<ref id="B39">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Mortality associated with benzodiazepines and benzodiazepine-related drugs among community-dwelling older people in finland a population-based retrospective cohort study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gisev]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Hartikainen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[TF]]></given-names>
</name>
<name>
<surname><![CDATA[Korhonen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bell]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<source><![CDATA[Can J Psychiatry]]></source>
<year>2011</year>
<volume>56</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>377-81</page-range></nlm-citation>
</ref>
<ref id="B40">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Pharmacologic treatment of insomnia disorder an evidence report for a clinical practice guideline by the american college of physicians]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wilt]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[MacDonald]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Brasure]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Olson]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Carlyle]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fuchs]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Ann Intern Med]]></source>
<year>2016</year>
<volume>165</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>103-12</page-range></nlm-citation>
</ref>
<ref id="B41">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Slow wave sleep in humans Role of 5-HT2A and 5-HT2C receptors]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sharpley]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Elliott]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Attenburrow]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cowen]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Neuropharmacology]]></source>
<year>1994</year>
<volume>33</volume>
<numero>3-4</numero>
<issue>3-4</issue>
<page-range>467-71</page-range></nlm-citation>
</ref>
<ref id="B42">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The effects of mirtazapine on sleep a placebo controlled, double-blind study in young healthy volunteers]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aslan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Isik]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Cosar]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<source><![CDATA[Sleep]]></source>
<year>2002</year>
<volume>25</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>677-9</page-range></nlm-citation>
</ref>
<ref id="B43">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Effects of mirtazapine on sleep polygraphic variables in major depression]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schittecatte]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dumont]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Machowski]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Cornil]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lavergne]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Wilmotte]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Neuropsychobiology]]></source>
<year>2002</year>
<volume>46</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>197-201</page-range></nlm-citation>
</ref>
<ref id="B44">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
<name>
<surname><![CDATA[Shin]]></surname>
<given-names><![CDATA[IS]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[YC]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
</person-group>
<source><![CDATA[Psychiatry Clin Neurosci]]></source>
<year>2008</year>
<volume>62</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>75-83</page-range></nlm-citation>
</ref>
<ref id="B45">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Appetite and cancer-associated anorexia a review]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Davis]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Dreicer]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Walsh]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Lagman]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[LeGrand]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
</person-group>
<source><![CDATA[J Clin Oncol]]></source>
<year>2004</year>
<volume>22</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1510-7</page-range></nlm-citation>
</ref>
<ref id="B46">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Prevalence and associated factors for decreased appetite among patients with stable heart failure]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Andreae]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Stromberg]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Arestedt]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[J Clin Nurs]]></source>
<year>2016</year>
<volume>25</volume>
<numero>11-12</numero>
<issue>11-12</issue>
<page-range>1703-12</page-range></nlm-citation>
</ref>
<ref id="B47">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Potential role of mirtazapine in underweight older adults]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hilas]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Avena-Woods]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Consult Pharm]]></source>
<year>2014</year>
<volume>29</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>124-30</page-range></nlm-citation>
</ref>
<ref id="B48">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Phase II trial of mirtazapine for cancer-related cachexia and anorexia]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Riechelmann]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Burman]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Tannock]]></surname>
<given-names><![CDATA[IF]]></given-names>
</name>
<name>
<surname><![CDATA[Rodin]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Zimmermann]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Hosp Palliat Care]]></source>
<year>2010</year>
<volume>27</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>106-10</page-range></nlm-citation>
</ref>
<ref id="B49">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Mirtazapine for the treatment of depression and nausea in breast and gynecological oncology]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Psychosomatics]]></source>
<year>2000</year>
<volume>41</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>356-9</page-range></nlm-citation>
</ref>
<ref id="B50">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Mirtazapine decreases the pain feeling in healthy participants]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arnold]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Vuadens]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Kuntzer]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Gobelet]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Deriaz]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin J Pain]]></source>
<year>2008</year>
<volume>24</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>116-9</page-range></nlm-citation>
</ref>
<ref id="B51">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Psychopharmacology of chronic pain a focus on antidepressants and atypical antipsychotics]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khouzam]]></surname>
<given-names><![CDATA[HR]]></given-names>
</name>
</person-group>
<source><![CDATA[Postgrad Med]]></source>
<year>2016</year>
<volume>128</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>323-30</page-range></nlm-citation>
</ref>
<ref id="B52">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Effectiveness of mirtazapine in the treatment of postherpetic neuralgia]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Christodoulou]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Douzenis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Moussas]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Lykouras]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[J Pain Symptom Manage]]></source>
<year>2010</year>
<volume>39</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>3-6</page-range></nlm-citation>
</ref>
<ref id="B53">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Phantom limb pain treatment with mirtazapine A case series]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kuiken]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Schechtman]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Harden]]></surname>
<given-names><![CDATA[RN]]></given-names>
</name>
</person-group>
<source><![CDATA[Pain Pract]]></source>
<year>2005</year>
<volume>5</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>356-60</page-range></nlm-citation>
</ref>
<ref id="B54">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Combinations of low-dose antidepressants and low-dose pregabalin as useful adjuvants to opioids for intractable, painful bone metastases]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nishihara]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Arai]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Yamamoto]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Nishida]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Arakawa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ushida]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<source><![CDATA[Pain Physician]]></source>
<year>2013</year>
<volume>16</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>E547-52</page-range></nlm-citation>
</ref>
<ref id="B55">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Godinez-Cubillo]]></surname>
<given-names><![CDATA[NC]]></given-names>
</name>
</person-group>
<source><![CDATA[Opioides. Uso clínico en el alivio del dolor]]></source>
<year>2009</year>
<publisher-loc><![CDATA[México DF, México ]]></publisher-loc>
<publisher-name><![CDATA[PyDESA]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B56">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Restless legs syndrome and psychiatric disorders]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mackie]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Winkelman]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
</person-group>
<source><![CDATA[Sleep Med Clin]]></source>
<year>2015</year>
<volume>10</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>351-7</page-range></nlm-citation>
</ref>
<ref id="B57">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Mirtazapine provokes periodic leg movements during sleep in young healthy men]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fulda]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kloiber]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Dose]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Lucae]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Holsboer]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Schaaf]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Sleep]]></source>
<year>2013</year>
<volume>36</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>661-9</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
